×
Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Lisdexamfetamine Dimesylate in Adults With Attention-Deficit/Hyperactivity Disorder PDF
$ 40.00
Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Lisdexamfetamine Dimesylate in Adults With Attention-Deficit/Hyperactivity Disorder PDF quantity
$ 40.00
×
Co-occurrence of Serious or Undiagnosed Medical Conditions With Bipolar Disorder Preventing Clinical Trial Randomization: A Case Series PDF
$ 40.00
Co-occurrence of Serious or Undiagnosed Medical Conditions With Bipolar Disorder Preventing Clinical Trial Randomization: A Case Series PDF quantity
$ 40.00
×
Threshold of Dopamine D2/3 Receptor Occupancy for Hyperprolactinemia in Older Patients With Schizophrenia PDF
$ 40.00
Threshold of Dopamine D2/3 Receptor Occupancy for Hyperprolactinemia in Older Patients With Schizophrenia PDF quantity
$ 40.00
×
Applicability of Telemedicine for Assessing Patients With Schizophrenia: Acceptance and Reliability PDF
$ 40.00
Applicability of Telemedicine for Assessing Patients With Schizophrenia: Acceptance and Reliability PDF quantity
$ 40.00
×
Decreased Nocturnal Oxytocin Levels in Anorexia Nervosa Are Associated With Low Bone Mineral Density and Fat Mass PDF
$ 40.00
Decreased Nocturnal Oxytocin Levels in Anorexia Nervosa Are Associated With Low Bone Mineral Density and Fat Mass PDF quantity
$ 40.00
×
Transdermal Patches for the Treatment of Neurologic Conditions in Elderly Patients: A Review PDF
$ 40.00
Transdermal Patches for the Treatment of Neurologic Conditions in Elderly Patients: A Review PDF quantity
$ 40.00
×
An Open-Label Study of Citalopram in the Treatment of Pathological Gambling PDF
$ 40.00
An Open-Label Study of Citalopram in the Treatment of Pathological Gambling PDF quantity
$ 40.00
×
Major Changes in Glucose Metabolism, Including New-Onset Diabetes, Within 3 Months After Initiation of or Switch to Atypical Antipsychotic Medication in Patients With Schizophrenia and Schizoaffective Disorder PDF
$ 40.00
Major Changes in Glucose Metabolism, Including New-Onset Diabetes, Within 3 Months After Initiation of or Switch to Atypical Antipsychotic Medication in Patients With Schizophrenia and Schizoaffective Disorder PDF quantity
$ 40.00
Coupon: Apply coupon
Update cart